Nationally renowned diabetes researcher, Dr. Alan C. Moses, appointed as
Chief Medical Officer for Novo Nordisk, North America
PRINCETON, N.J., March 12 /CNW/ -- Novo Nordisk, a world leader in
diabetes care, today announced the appointment of Dr. Alan C. Moses as chief
medical officer, North America. In his new role, Dr. Moses, who has been with
Novo Nordisk since 2004, will provide strategic input and oversight into the
company's breakthrough diabetes and biopharmaceutical clinical research and
medical affairs. In addition, Dr. Moses will work closely with senior
colleagues in Denmark on global Novo Nordisk research and development programs
"As the world's leader in diabetes care, Novo Nordisk is committed to
remaining at the forefront of research and development to improve treatments
for the patients we serve," said Dr. Henrik Rasmussen, vice president of
clinical development, medical and regulatory affairs, Novo Nordisk. "With his
unique clinical expertise, strong relationships in healthcare and leadership
abilities, Dr. Moses will have a vital role in working toward Novo Nordisk's
ambition of changing diabetes."
Dr. Moses was formerly senior vice president and chief medical officer at
the Joslin Diabetes Center and joined Novo Nordisk in April of 2004 as
associate vice president of medical affairs and since then has also assumed
responsibility for clinical research in diabetes.
Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard
Medical School affiliated institutions where he rose to the rank of Professor
of Medicine. He has written over 100 peer-reviewed articles on the treatment
of diabetes and has been recognized both locally and nationally for his
research in diabetes and growth factors.
Dr. Moses received a Bachelor of Science from Duke University and a
Medical Doctorate from Washington University School of Medicine prior to
training at Barnes Hospital in St. Louis, MO, the National Institutes of
Health in Bethesda, MD, and Tufts-New England Medical Center in Boston. Dr.
Moses is board certified by the American Board of Internal Medicine and has a
subspecialty certification in Endocrinology and Metabolism.
Novo Nordisk is a healthcare company with an 80-year history of
innovation and achievement in diabetes care. In addition to diabetes care,
Novo Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment to
economic success, environmental soundness, and social responsibility to
employees and customers. With headquarters in Denmark, Novo Nordisk employs
more than 23,600 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO'. For global information, visit novonordisk.com; for
United States information, visit novonordisk-us.com.
For further information:
For further information: Media - Susan Jackson, +1-609-919-7776; or
Investors - Christian Qvist Frandsen, +1-609-919-7937 Web Site: